Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Editorial

  • Editorial
    Cancer Immunology Essentials: A Preface
    Glenn Dranoff
    Cancer Immunol Res April 1 2014 2 (4) 287-287; DOI:10.1158/2326-6066.CIR-14-0043

Masters of Immunology

  • Masters of Immunology
    The Biology and Medical Implications of Interleukin-6
    Toshio Tanaka and Tadamitsu Kishimoto
    Cancer Immunol Res April 1 2014 2 (4) 288-294; DOI:10.1158/2326-6066.CIR-14-0022

Cancer Immunology at the Crossroads: Experimental Immunotherapies

  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
    Oncolytic Viruses and Their Application to Cancer Immunotherapy
    E. Antonio Chiocca and Samuel D. Rabkin
    Cancer Immunol Res April 1 2014 2 (4) 295-300; DOI:10.1158/2326-6066.CIR-14-0015

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
    Chris P. Miller, Jason D. Thorpe, Amanda N. Kortum, Catherine M. Coy, Wei-Yi Cheng, Tai-Hsien Ou Yang, Dimitris Anastassiou, J. David Beatty, Nicole D. Urban and C. Anthony Blau
    Cancer Immunol Res April 1 2014 2 (4) 301-306; DOI:10.1158/2326-6066.CIR-13-0189

    Miller and colleagues analyzed archived annotated breast tumors and evaluated patient data in three public cohorts; they found an inverse association between JAK2 mRNA and risk of recurrence and a correlation between JAK2 expression, improved outcomes, and infiltrating T cells.

Research Articles

  • Research Articles | AuthorChoice
    Apoptosis-Regulated Low-Avidity Cancer-Specific CD8+ T Cells Can Be Rescued to Eliminate HER2/neu–Expressing Tumors by Costimulatory Agonists in Tolerized Mice
    Chelsea M. Black, Todd D. Armstrong and Elizabeth M. Jaffee
    Cancer Immunol Res April 1 2014 2 (4) 307-319; DOI:10.1158/2326-6066.CIR-13-0145

    Black and colleagues identify, for the first time, that low-avidity antitumor T cells are ineffective due to increased expression of proapoptotic proteins promoting activation-induced T-cell death, which can be overcome by TNFR agonists, implicating their use in cancer immunotherapy.

  • Research Articles
    PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
    Alexander W. MacFarlane IV, Mowafaq Jillab, Elizabeth R. Plimack, Gary R. Hudes, Robert G. Uzzo, Samuel Litwin, Essel Dulaimi, Tahseen Al-Saleem and Kerry S. Campbell
    Cancer Immunol Res April 1 2014 2 (4) 320-331; DOI:10.1158/2326-6066.CIR-13-0133

    MacFarlane and colleagues show that tumor resection reverses PD-1 expression on peripheral blood (PB) immune cells and suggest that PD-1 blockade for renal cell carcinoma patients with PD-1 expression on PB cells would be most effective prior to surgery, especially in early-stage cancer.

  • Research Articles
    Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome
    Bridget Charbonneau, Kirsten B. Moysich, Kimberly R. Kalli, Ann L. Oberg, Robert A. Vierkant, Zachary C. Fogarty, Matthew S. Block, Matthew J. Maurer, Krista M. Goergen, Brooke L. Fridley, Julie M. Cunningham, David N. Rider, Claudia Preston, Lynn C. Hartmann, Kate Lawrenson, Chen Wang, Jonathan Tyrer, Honglin Song, Anna deFazio, Sharon E. Johnatty, Jennifer A. Doherty, Catherine M. Phelan, Thomas A. Sellers, Starr M. Ramirez, Allison F. Vitonis, Kathryn L. Terry, David Van Den Berg, Malcolm C. Pike, Anna H. Wu, Andrew Berchuck, Aleksandra Gentry-Maharaj, Susan J. Ramus, Brenda Diergaarde, Howard Shen, Allan Jensen, Janusz Menkiszak, Cezary Cybulski, Jan Lubiński, Argyrios Ziogas, Joseph H. Rothstein, Valerie McGuire, Weiva Sieh, Jenny Lester, Christine Walsh, Ignace Vergote, Sandrina Lambrechts, Evelyn Despierre, Montserrat Garcia-Closas, Hannah Yang, Louise A. Brinton, Beata Spiewankiewicz, Iwona K. Rzepecka, Agnieszka Dansonka-Mieszkowska, Petra Seibold, Anja Rudolph, Lisa E. Paddock, Irene Orlow, Lene Lundvall, Sara H. Olson, Claus K. Hogdall, Ira Schwaab, Andreas du Bois, Philipp Harter, James M. Flanagan, Robert Brown, James Paul, Arif B. Ekici, Matthias W. Beckmann, Alexander Hein, Diana Eccles, Galina Lurie, Laura E. Hays, Yukie T. Bean, Tanja Pejovic, Marc T. Goodman, Ian Campbell, Peter A. Fasching, Gottfried Konecny, Stanley B. Kaye, Florian Heitz, Estrid Hogdall, Elisa V. Bandera, Jenny Chang-Claude, Jolanta Kupryjanczyk, Nicolas Wentzensen, Diether Lambrechts, Beth Y. Karlan, Alice S. Whittemore, Hoda Anton Culver, Jacek Gronwald, Douglas A. Levine, Susanne K. Kjaer, Usha Menon, Joellen M. Schildkraut, Celeste Leigh Pearce, Daniel W. Cramer, Mary Anne Rossing, Georgia Chenevix-Trench, for the AOCS group, ACS, Paul D.P. Pharoah, Simon A. Gayther, Roberta B. Ness, Kunle Odunsi, Lara E. Sucheston, Keith L. Knutson and Ellen L. Goode
    Cancer Immunol Res April 1 2014 2 (4) 332-340; DOI:10.1158/2326-6066.CIR-13-0136

    Charbonneau and colleagues analyzed the genotypes and outcomes of 10,084 women from Ovarian Cancer Association Consortium studies and identified polymorphisms in regulatory T-cell genes associated with the survival of patients with endometrioid (IL2RA) and clear cell (CTLA4) invasive epithelial ovarian cancer.

  • Research Articles
    Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells
    Junko Matsuzaki, Takemasa Tsuji, Immanuel Luescher, Lloyd J. Old, Protul Shrikant, Sacha Gnjatic and Kunle Odunsi
    Cancer Immunol Res April 1 2014 2 (4) 341-350; DOI:10.1158/2326-6066.CIR-13-0138

    Matsuzaki, Tsuji, and colleagues show that a unique subset of NY-ESO-1–specific CD4+ T cells directly recognize cancer cells and short 8-9-mer peptides via nonclassical pathways involving proteasomal degradation, transporter-associated antigen processing (TAP)–mediated peptide transport, and endosomal recycling.

  • Research Articles
    MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
    Laura J. Vella, Anupama Pasam, Nektaria Dimopoulos, Miles Andrews, Ashley Knights, Anne-Laure Puaux, Jamila Louahed, Weisan Chen, Katherine Woods and Jonathan S. Cebon
    Cancer Immunol Res April 1 2014 2 (4) 351-360; DOI:10.1158/2326-6066.CIR-13-0181

    Vella and colleagues show that inhibition of BRAF (dabrafenib) had no effect on healthy donor T cells and monocyte-derived dendritic cells (MoDC), but that MEK inhibition (trametinib) suppressed T-cell proliferation, cytokine production, antigen-specific expansion, and MoDC cross-presentation.

  • Research Articles
    PD-L1 Expression in Triple-Negative Breast Cancer
    Elizabeth A. Mittendorf, Anne V. Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M. Gonzalez-Angulo, Argun Akcakanat, Akhil Chawla, Michael Curran, Patrick Hwu, Padmanee Sharma, Jennifer K. Litton, Jeffrey J. Molldrem and Gheath Alatrash
    Cancer Immunol Res April 1 2014 2 (4) 361-370; DOI:10.1158/2326-6066.CIR-13-0127

    Using tissue microarrays containing 105 triple-negative breast cancer (TNBC) specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD-L1 expression, providing a rationale for therapeutic targeting of PD-L1 for TNBC.

  • Research Articles
    Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
    Jun Yao, Otavia L. Caballero, W.K. Alfred Yung, John N. Weinstein, Gregory J. Riggins, Robert L. Strausberg and Qi Zhao
    Cancer Immunol Res April 1 2014 2 (4) 371-379; DOI:10.1158/2326-6066.CIR-13-0088

    Yao and colleagues surveyed the expression and methylation of CT antigens and clinicopathologic features of ten cancers in The Cancer Genome Atlas RNAseq datasets, identifying multiple tumor subtype-specific CT antigens to be studied as potential biomarkers and targets for immunotherapy.

Back to top
PreviousNext
Cancer Immunology Research: 2 (4)
April 2014
Volume 2, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Editorial
  • Masters of Immunology
  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
  • Cancer Immunology Miniatures
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Characterization of Murine Syngeneic Tumor Models
  • PD-L1 in Triple-Negative Breast Cancer
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement